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abstract: Force generation in smooth muscle is driven by phosphorylation of myosin light chains (MYL), which is regulated by the equi-
librium between the activities of myosin light chain kinase (MYLK) and myosin phosphatase (MYLP). MYLK is activated by Ca
2+-calmodulin
whereas MYLP is inhibited by phosphorylation of its myosin-binding subunit (MYPT1) by Ca
2+-independent mechanisms, leading to
generation of increased MYL phosphorylation and force for a given intracellular Ca
2+ concentration, a phenomenon known as ‘calcium-
sensitization’. The regulation of MYPT1 phosphorylation in human myometrium, which shows increasing phasic contractility at the onset
of labour, has yet to be fully investigated. Here, we explore phosphorylation of MYPT1 at Thr696 and Thr853, alongside phosphorylation
of MYL, in fresh human myometrial tissue and cultured myometrial cells. We report that pMYPT1 (Thr853) levels are dependent on the
activity of Rho-associated kinase (ROCK), determined using the ROCK inhibitor g-H-1152 and siRNA-mediated knockdown of ROCK1/
2, and are highly correlated to ppMYL (Thr18/Ser19) levels. Pharmacological inhibition of ROCK was associated with a decrease in oxytocin
(OXT)-stimulated contractility of myometrial strips in vitro. Moreover, we have measured pMYPT1 and pMYL levels between and during
spontaneous and OXT-stimulated phasic contractions by rapidly freezing contracting muscle, and demonstrate for the ﬁrst time functional
coupling between increases in pMYPT1 (Thr853), ppMYL (Thr18/Ser19) and phasic contractility that is ROCK-dependent. The combined
approach of measuring contractility and phosphorylation has demonstrated that the phosphorylation of MYPT1 (Thr853) changes dynam-
ically with each contraction and has elucidated a deﬁned role for ROCK in regulating myometrial contractility through MYLP, providing new
insights into uterine physiology which will stimulate further research into treatments for preterm labour.
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Introduction
The pregnant uterus is a remarkable smooth muscle organ; after
implantation of the embryo it grows and stretches to allow the devel-
opment of the fetus and placenta, and is able to carry a considerable
load for many weeks while remaining in a state of relative quiescence.
However, the mechanisms involved in the transition from uterine
quiescence to contractility at the onset of labour are not known and
the endocrine or paracrine changes that promote parturition in
women remain elusive. As a consequence, the prediction and
management of complications such as preterm labour or uterine
dystocia are poor, resulting in potentially severe complications for
mother and baby.
Myometrium is a phasic smooth muscle and cycles of relaxation and
contraction depend on the reversible equilibrium between unpho-
sphorylated (MYL) and phosphorylated myosin light chain (P-MYL).
As in other types of smooth muscle, in myometrium this equilibrium
is driven by the opposing activities of myosin light chain kinase
(MYLK) and myosin phosphatase (MYLP). MYLK is a calcium-
dependent enzyme which responds rapidly to changes in intracellular
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2+]i) through interaction with Ca
2+-calmodulin. On the
other hand MYLP activity can be regulated by phosphorylation in a
Ca
2+-independent manner. Oxytocin (OXT) and other contractile
agonists stimulate uterine contractility by binding to speciﬁc G protein-
coupled receptors and promoting Ca
2+ entry into the cells through
activation of the Gq/phospholipase C signalling pathway (Lopez
Bernal, 2003). Moreover, inhibition of MYLP potentiates the effect
of MYLK, and the equilibrium requires less [Ca
2+]i to shift towards
P-MYL, a phenomenon called ‘Ca
2+-sensitization’ (Somlyo and
Somlyo, 2003).
Endogenous OXT is one of the most potent uterotonic agonists,
and for many years it has been known that the sensitivity of the
uterus to OXT increases dramatically in pregnancy (Caldeyro-Barcia
and Theobald, 1968; Turnbull and Anderson, 1968), partly as a conse-
quence of increased myometrial OXT receptor density (Fuchs et al.,
1984; Bossmar et al., 1994). Moreover, synthetic OXT is commonly
used for the induction and augmentation of labour, although many
uncertainties remain about its mechanism of action. For instance,
analysis of Ca
2+-tension relationship in pregnant myometrial strips
reveals a signiﬁcant component of Ca
2+-sensitization during
OXT-induced contractions (McKillen et al., 1999; Woodcock et al.,
2004); however, the pathways involved have not been fully elucidated.
The MYLP holoenzyme is composed of three subunits: a 38 kDa
catalytic protein phosphatase subunit (PP1C); a large 110–130 kDa
regulatory myosin-binding subunit (MYPT1, also known as
PPP1R12A or MBP); and a small 20 kDa subunit (Hartshorne,
1998). The regulation of the MYPT1 in human myometrium is
complex and requires detailed investigation. Experimental evidence
shows that in smooth muscle the C-terminal end of MYPT1 is the
target for several protein kinases, including Rho-associated kinase
(ROCK) (Feng et al., 1999), integrin-linked kinase (ILK) (Muranyi
et al., 2002) and zipper-interacting protein kinase (MacDonald et al.,
2001; Borman et al., 2002). Phosphorylation of the C-terminal end
of MYPT1 occurs simultaneously or independently at two different
sites, namely Thr696 and Thr853, and it is proposed that phosphoryl-
ation of either or both sites blocks MYLP activity by a mechanism of
auto-inhibition (Khromov et al., 2009). Phosphorylation by ROCK of
one or both of these sites is Ca
2+-independent and has been demon-
strated in several cell types, including epithelial cells (Kawano et al.,
1999), endothelial cells (Somlyo et al., 2003; Choi et al., 2009), plate-
lets (Pandey et al., 2006), smooth muscle cells (Ito et al., 2003; Kita-
zawa et al., 2003; Patil and Bitar, 2006; Wang et al., 2006, 2009;
Mizuno et al., 2008) and rat uterine strips (Tahara et al., 2002). It
has therefore been proposed that phosphorylation of these sites
may play a role in Ca
2+-sensitization, however, little is known about
their regulation and function in human myometrium. Inhibition of
MYLP phosphorylation could explain the decrease in Ca
2+-
sensitization, and hence relaxation, evoked by ROCK inhibitors
during OXT-induced myometrial contractility (Woodcock et al.,
2004), however, other ROCK targets such as MYL itself (Amano
et al., 1996; Katoh et al., 2001; Ueda et al., 2002), could be involved.
MYLP can also be regulated through the 17 kDa protein kinase C
(PKC)-activated phosphatase inhibitor (CPI-17), which is capable of
inhibiting MYLP activity, thus potentiating P-MYL levels, when phos-
phorylated itself at Thr38 (Eto et al., 1995). Phosphorylation of
Thr38 in response to agonist stimulation has been shown to be
dependent on PKC, ROCK or ILK activities in vascular smooth
muscle (Kitazawa et al., 2000; Pang et al., 2005; Huang et al., 2006).
Up-regulation of CPI-17 mRNA and protein expression have been
demonstrated during pregnancy, and these changes may explain the
increased ability of PKC to mediate contraction of human myome-
trium during gestation (Ozaki et al., 2003).
We and others (Moore et al., 2000; Moran et al., 2002; Lartey et al.,
2006, 2007) have found that extracts of pregnant human myometrium
contain proteins of the Rho family of small GTPases and have demon-
strated a pregnancy-related up-regulation of RND2 and RND3 in
human myometrium (Lartey et al., 2006). RND proteins inhibit RhoA-
mediated activation of ROCK by binding to a site which prevents
RhoA–ROCK interaction. This increase in RND protein expression
in rabbit myometrium is functionally coupled to a decrease in
agonist- and GTP-induced Ca
2+-sensitization during gestation (Cario-
Toumaniantz et al., 2003). Moreover, the gestation-related
up-regulation of RND2 and RND3 in human myometrium is asso-
ciated with a loss of MYPT1 phosphorylation at Thr696 (a potential
phosphorylation site of ROCK) in the pregnant samples (Lartey
et al., 2006), suggesting an increase in the activity of MYLP in preg-
nancy. Furthermore, we have found that the level of active
(GTP-bound) RhoA is elevated in pregnant compared with non-
pregnant myometrium, and interestingly this increase is exacerbated
in spontaneous preterm labour (Lartey et al., 2007). Additional
Rho-effectors such as PKN1 and DIAPH1 are also up-regulated with
pregnancy (Lartey et al., 2007). We and others have demonstrated
no change in ROCK1 expression with pregnancy or labour (Riley
et al., 2005; Lartey et al., 2007), while ROCK2 levels are decreased
in pregnant versus non-pregnant myometrial tissue (Riley et al., 2005).
The purpose of this manuscript was to demonstrate phosphoryl-
ation of MYPT1 in pregnant human myometrial tissue and to clarify
the involvement of ROCK under non- and OXT-stimulated condi-
tions. Measurements of myometrial contractility and preservation of
phosphorylation states during contraction and relaxation phases
were used to elucidate that functional coupling exists between
force, MYL (Thr18/Ser19) and MYPT1 (Thr853) phosphorylation
that is ROCK-dependent. We have used ROCK inhibitors and have
depleted ROCK1 and ROCK2 isoforms in human myometrial cells
to demonstrate that Thr853 is the primary target for ROCK on
MYPT1, and that both isoforms contribute to phosphorylation.
Materials and Methods
Tissue collection
This study was approved by the North Somerset and South Bristol
Research Ethics Committee and all women gave informed written
consent. Myometrium was obtained from the upper border of the incision
in women undergoing elective (not in labour) sections at term (37–41
weeks gestation). Indications for Caesarean sections included fetal malpo-
sition, previous section and maternal request. Women with signs of infec-
tion or who had received syntocinon for labour augmentation were
excluded. The tissue was washed in ice-cold isotonic saline and trans-
ported to the laboratory where it was used to prepare tissue strips or
freshly dispersed myometrial cells.
Materials
The following chemicals and reagents were obtained from the indicated
sources: ON-TARGET plus smart pool siRNAs for human ROCK1
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(gene Id: 5586); ON-TARGET plus non-targeting pool siRNA and Dhar-
mafect 1 transfection reagent were purchased from Abgene (Epsom,
UK). Collagenase type II, dispase, DMEM, fetal calf serum (FCS) and
Alexa Fluorw 488 phalloidin were purchased from Invitrogen (Paisley,
UK); elastase and DNAse were purchased from Sigma Aldrich (Poole,
UK). ROCK inhibitor glycyl-H-1152-dihydrochloride (g-H-1152) and
OXT were purchased from Merck (Darmstadt, Germany). PKC inhibitor
bisindolylmaleimide I (BIS1, GF 109203X or Go ¨ 6850) was purchased
from Tocris Bioscience (Bristol, UK). Phospho-MYL (Thr18/Ser19),
phospho-MYL (Ser19), phospho-MYPT1 (Thr853), phospho-MYPT1
(Thr696), MYPT1 and ROCK1 antibodies were purchased from Cell
Signalling Technology (Danvers, MA, USA). MYL and ROCK2 antibodies
were purchased from Abcam (Cambridge, UK). All other basic chemicals
were supplied by Sigma Aldrich (Poole, UK) unless otherwise stated.
Measurement of myometrial contractility
Contractility measurements were carried out using a four chamber
Myobath-II system from World Precision Instruments (WPI, Stevenage,
UK). Strips of freshly isolated myometrial tissue were mounted using
s-shaped hooks within a 10 ml chamber, and equilibrated in oxygenated
Krebs solution (4.7 mM KCl, 1.25 mM MgSO4, 2.5 mM NaH2PO4,
1.25 mM CaCl2, 130 mM NaCl, 25 mM NaHCO3, 11.1 mM glucose and
10 mM Hepes pH 7.6) at 378C for 45 min with three buffer changes.
Hooks were connected to force transducers and data were recorded elec-
tronically using the Lab-Trax data acquisition system (WPI). Resting
tension was set to 2 g and readjusted during the equilibrium phase, and
spontaneous contractions were observed within  1 h of the ﬁnal buffer
change. Any strips that failed to contract during this time were excluded
from further study. Agonists or inhibitors were added directly to the
buffer chamber during experiments.
For g-H-1152 dose–response experiments (Figs 1 and 2), spontan-
eously contracting myometrial strips were treated with 10 nM OXT
until consistent contractions were achieved for a period of 30 min. Cumu-
lative additions of g-H-1152 (1×10
29 M, 1×10
28 M, 1 × 10
27 M,
1 × 10
26 M and 1 × 10
25 M) were added at 20 min intervals and
dimethylsulphoxide (DMSO) control (maximum 0.1%) was added to a
time-matched control strip present during every experiment. After the
ﬁnal g-H-1152 dose, muscle strips were quickly dismounted from the
apparatus following a phasic contraction and rapidly frozen in liquid
nitrogen for phosphorylation studies.
Contractility data were analysed using Data-Trax software (WPI), from
which integrated area under curve and minimum (baseline force) were cal-
culated. For g-H-1152 dose–response experiments, data calculated for
each dose during a 20 min window were expressed as a percentage of
the OXT-induced contractility prior to g-H-1152 or DMSO additions.
Data were further normalized using those from the control (DMSO
treated) strip to take into account decreases in contractility over the
experimental time course. Data were analysed using non-linear regression
and ﬁtted with sigmoidal dose–response curves using Prism v4.00 (Graph-
Pad Software, La Jolla, CA, USA). Statistical analysis was carried out using
repeated-measures analysis of variance (ANOVA) and Tukey’s post hoc
tests to compare each dose to the non-treated value.
For experiments comparing phosphorylation in relaxed versus contract-
ing tissue, spontaneously contracting myometrial strips were stimulated
with or without 10 nM OXT for 40 min, and for a further 40 min in the
presence or in the absence of 1 mM g-H-1152 (Figs 3 and 4). Following
these treatments, the strips were rapidly removed from the apparatus at
the peak of (contracting), or immediately following (relaxed), a phasic
contraction and snap-frozen in liquid nitrogen. The freezing process
took an average of 5 s to complete, and the tissue was stored at
2808C until further use. The Myobath II system used in these studies
had four chambers and only four conditions could be compared simultan-
eously. The experiments on spontaneously contracting tissue and OXT-
stimulated tissue are therefore independent and are presented as such,
each being carried out with tissue from seven different women.
Figure 1 Inhibition of ROCK with g-H-1152 causes dose-dependent decreases in phasic contractility and baseline force of freshly isolated human
myometrium. (A) Cumulative doses of g-H-1152 were added at 20 min intervals to myometrial strips contracting in response to 10 nM OXT. (B)
DMSO (maximum 0.1%) was added to time-matched control strips. (C) Integrated area under curve and (D) baseline force were calculated for
each 20 min interval, g-H-1152 data were expressed as a percentage of the non-treated values and normalized to those obtained from the
control strip. Data points represent mean+SEM, n ¼ 5; and were ﬁtted to sigmoidal dose–response curves. Statistical signiﬁcance was determined
using repeated-measures ANOVA and Tukey’s post hoc test; *P , 0.05, **P , 0.01 and ***P , 0.001 compared with non-treated values.
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Frozen tissue strips were homogenized in buffer (25 mM Tris pH 6.8, 2%
SDS, 10% glycerol, 50 mM b-glycerophosphate and 1 mg/ml each pepsta-
tin, leupeptin and antipain) at  100 mg/ml using a Polytron homogenizer
at 208C. Lysates were immediately heated to 958C for 5 min, and cleared
by centrifugation at 16 000g for 10 min at 208C. Protein concentration was
determined using the BCA assay kit (Perbio Science, Cramlington, UK)
before 12.5 mM dithiothreitol and 0.002% bromophenol blue were
added prior to electrophoresis.
Myometrial cell culture
Myometrial tissue was digested in serum-free Dulbecco’s Modiﬁed Eagle’s
medium (DMEM) containing 300 U/ml collagenase (type II), 0.3 U/ml
dispase, 30 U/ml DNase I and 0.09 U/ml elastase at 378C for 3 h with
shaking. Liberated smooth muscle cells were then grown in adherent
cell culture with DMEM containing 10% FCS, 100 U/ml penicillin and
100 mg/ml streptomycin at 378C. Experiments were carried out by
plating cells of passage six or lower at 2.7 × 10
4/cm
2 in 12- or 24-well
plates and growing to conﬂuency over 3 days. Cells were serum-starved
for 4 h prior to experiments, and after treatment were washed with
phosphate-buffered saline (PBS), lysed directly in boiling SDS–PAGE
sample buffer (25 mM Tris pH 6.8, 10% glycerol, 2% SDS, 12.5 mM dithio-
threitol and 0.002% bromophenol blue), and used for immunoblotting as
described below.
Fluorescence staining of stress ﬁbres
Cells were seeded on glass coverslips at 1.4 × 10
4/cm
2 and grown over-
night. Cells were starved for 4 h before being treated with 1 mM g-H-1152
or 2 mM BIS1 for 40 min. Cells were washed in PBS and ﬁxed with 3.7%
paraformaldehyde for 15 min at room temperature. After ﬁxation, cover-
slips were washed 3 × 5 min with PBS and permeabilized with 0.1%
Triton-X 100 in PBS for 15 min. Cells were then blocked with 1%
bovine serum albumin (BSA) in PBS for 20 min. Filamentous actin was
stained with Alexa Fluor 488w phalloidin (Invitrogen, Paisley, UK) at
 165 nM with 1% BSA in PBS. Staining was performed for 20 min at
room temperature protected from light. The coverslips were washed
3 × 5 min with PBS and subsequently mounted onto slides with Vecta-
shield mounting medium containing DAPI (Vector Laboratories Ltd, Peter-
borough, UK) to stain nuclei, prevent rapid fading and allow short-term
storage. Filamentous actin pools were visualized with an upright ﬂuores-
cence microscope (Leica DMRB; Leica, Wetzlar, Germany) and images
Figure 2 Phosphorylation of MYL and MYPT1 is reduced in isolated myometrial strips treated with ROCK inhibitor g-H-1152. Myometrial strips
treated with 10 nM OXT with and without cumulative additions of g-H-1152 to a maximum of 10 mM (as in Fig. 1), were snap frozen at the end of the
experiment during a relaxed phase. (A) Solubilized proteins were subject to SDS–PAGE and immunoblotting for ppMYL (Thr18/Ser19), pMYL
(Ser19), MYL, pMYPT1 (Thr853), pMYPT1 (Thr696) and MYPT1.(B–E) Signal from the phospho-speciﬁc antibody was normalized to that obtained
from the associated total antibody, and expressed as a percentage of the OXT-treated value. Bars represent mean + SEM, and statistical analyses
were performed using paired Student’s t-tests, *P , 0.05, **P , 0.01, ***P , 0.001, n ¼ 5.
268 Hudson et al.were captured with a Leica DFC340FX camera and processed using Leica
Application Suite 3.3.1.
siRNA-mediated knockdown of ROCK,
ROCK2, PKN1 and PKN2
Myometrial cells grown to 50% conﬂuency were incubated in the presence
of 25 nM siRNA (ROCK1, ROCK2, PKN1, PKN2 or non-targeting) and
3% (v/v) Dharmafect 1 reagent in DMEM/FCS for 72 h. Cells were
lysed as above and protein knockdown veriﬁed by immunoblotting with
ROCK1, ROCK2, PKN1 and PKN2 antibodies.
SDS–PAGE, immunoblotting and
quantiﬁcation of immuno bands
Cell or tissue lysates (15 or 50 mg protein, respectively) were resolved
using 10% Bis-Tris gels (357 mM Bis-Tris pH 6.75, 10% acrylamide,
0.27% bis-acrylamide) and MOPS running buffer (250 mM MOPS,
250 mM Tris, 5 mM EDTA, 0.5% SDS and 5 mM sodium bisulﬁte). Pro-
teins were transferred to polyvinylidene diﬂuoride membrane (GE
Healthcare, Buckinghamshire, UK) by wet transfer at 80 mA for 1 h
in a buffer containing 25 mM Tris, 192 mM glycine, 10% methanol
and 0.01% SDS. Membranes were blocked in 5% BSA in Tris-buffered
Figure 3 OXT-stimulated phasic contractions of freshly isolated myometrium are associated with ROCK-dependent increases in phosphorylation of
MYL (Thr18/Ser19) and MYPT1 (Thr853). Spontaneously contracting myometrial strips were treated with 10 nM OXT for 40 min and for a further
40 min in the presence or in the absence of 1 mM g-H-1152 (A and B). Strips were subsequently snap-frozen at the peak of (contracting), or imme-
diately following (relaxed), a phasic contraction. Solubilized proteins were subjected to SDS–PAGE and immunoblotting. Signals from phospho-speciﬁc
antibodies were normalized to those obtained from their associated total antibodies, and data were expressed as a percentage of the control value
(OXT, relaxed). (C) ppMYL (Thr18/Ser19) levels, (D) pMYL (Ser19) levels, (E) pMYPT1 (Thr853) levels, (F) pMYPT1 (Thr696) levels; bars represent
mean + SEM, n ¼ 7. Data were analysed using two-way ANOVA and Bonferroni post hoc tests to determine both the contribution of contraction and
of g-H-1152 treatment. *P , 0.05, **P , 0.01 for the effect of contraction,
††P , 0.01 for the effect of g-H-1152 on contracting tissue.
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antibodies (1 mg/ml in 5% BSA/TBS-T) overnight at 48C. After
washing 6 × 5 min in TBS-T, membranes were incubated with a horse-
radish peroxidase-conjugated goat anti-rabbit antibody (Cell Signalling
Technology, Danvers, MA, USA; 1:5000) in TBS-T for 1 hour at
room temperature. Membranes were washed for a further 6 × 5m i n
and bands visualized using an enhanced chemiluminescence system
(GE Healthcare, Buckinghamshire, UK). Membranes were probed
initially with phospho-speciﬁc antibodies and re-probed with the
equivalent total antibody after incubating for 3 h in stripping buffer
(20 mM glycine and 1% SDS, pH 2). Bands were quantiﬁed by densi-
tometry using Quantity One software (Bio-Rad, Hemel Hempstead,
UK), and care was taken to avoid saturation of signals. Raw data
were normalized using a control for each experiment, and the level
of phosphorylation was always normalized using the level of equivalent
total protein.
Figure 4 Spontaneous phasic contractions of freshly isolated myometrium are associated with ROCK-dependent increases in phosphorylation of
MYL (Thr18/Ser19) and MYPT1 (Thr853). Spontaneously contracting myometrial strips were treated with or without 1 mM g-H-1152 for 40 min
(A and B). Strips were subsequently snap-frozen at the peak of (contracting), or immediately following (relaxed), a phasic contraction. Solubilized
proteins were subjected to SDS–PAGE and immunoblotting. Signals from phospho-speciﬁc antibodies were normalized to those obtained from
their associated total antibodies, and data were expressed as a percentage of the control value (OXT, relaxed). (C) ppMYL (Thr18/Ser19) levels,
(D) pMYL (Ser19) levels, (E) pMYPT1 (Thr853) levels, (F) pMYPT1 (Thr696) levels; bars represent mean + SEM, n ¼ 7. Data were analysed
using two-way ANOVA (
‡P , 0.05 for the overall effect of g-H-1152) and Bonferroni post hoc tests to determine both the contribution of contraction
(*P , 0.05 and **P , 0.01) and of g-H-1152 treatment on contracting tissue (
††P , 0.01).
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ROCK inhibitor g-H-1152 causes
dose-dependent reductions in
OXT-stimulated phasic contractility of
freshly isolated human myometrial strips
Glycyl-H-1152-dihydrochloride (g-H-1152) is a glycated isoquinoline
derived from the ROCK inhibitor HA-1077 (Fasudil), and is a cell
permeable, reversible and ATP-competitive inhibitor of ROCK1/2.
It shows greater potency than both HA-1077 and the commonly
used ROCK inhibitor Y27632 (IC50 for ROCK2 ¼ 11.8 versus 158
and 220 nM, respectively) and shows 100-fold selectivity for ROCK
over other protein kinases such as PKA and PKC (Ishizaki et al.,
2000; Tamura et al., 2005). While others have shown previously
that ROCK inhibitor Y27632 can reduce spontaneous and
OXT-induced contractility of human myometrium in vitro (Kupittaya-
nant et al., 2001; Moran et al., 2002; Woodcock et al., 2004), the
effect of g-H-1152 on contractility has yet to be investigated. Repre-
sentative contractility traces of g-H-1152-treated and time-matched
DMSO-treated control strips are shown in Fig. 1A and B. When
added to OXT-stimulated myometrial strips, g-H-1152 caused dose-
dependent reductions in phasic contractility (determined by integrated
area) and in baseline force, with statistically signiﬁcant reductions seen
from 100 nM g-H-1152 (Fig. 1C and D, P , 0.01 and P , 0.05,
respectively). The net contractility remaining at the highest dose
used, 10 mM H-1152, was 31.8+6.3% for integrated area (P ,
0.001) and 51.6+6.1% for baseline force (P , 0.001).
The relaxing effect of g-H-1152 is associated
with reductions in MYL and MYPT1
phosphorylation in freshly isolated
myometrial tissue
In order to analyse tension–phosphorylation relationships,
g-H-1152-treated myometrial strips (from Fig. 1) were snap-frozen
after contractility had been measured, and phosphorylation of MYL
and MYPT1 was analysed by immunoblotting. Phospho-speciﬁc anti-
bodies were used to detect phosphorylation of MYPT1 at Thr696
or Thr853; and phosphorylation of MYL was detected using two
separate antibodies: one for Ser19 and another for dual phosphoryl-
ation at both Thr18 and Ser19. Phosphorylation of Ser19 requires
less MYLK activity and hence precedes phosphorylation at Thr18
(Ikebe and Hartshorne, 1985), but the latter increases myosin
ATPase activity beyond that of Ser19 alone (Ikebe et al., 1988). A
56.4+8.2% reduction in ppMYL (Thr18/Ser19) was measured in
strips treated with 10 mM g-H-1152 when compared with non-treated
strips (P , 0.01); however, there was no signiﬁcant decrease in phos-
phorylation of MYL at the Ser19 site alone (Fig. 2B and C). This ﬁnding
indicates that ROCK inﬂuences the phosphorylation of Thr18 to a
greater extent than Ser19. To investigate the possibility that ROCK-
mediated MYPT1 phosphorylation and subsequent MYLP inhibition
contribute to MYL phosphorylation in myometrial tissue, phosphoryl-
ation of MYPT1 was monitored. Phosphorylation at Thr853, and to a
lesser extent at Thr696, was signiﬁcantly reduced by g-H-1152
(82.7+2.6% reduction, P , 0.001 and 24.9+12.8% reduction,
P , 0.05, respectively; Fig. 2D and E). These data indicate that
ROCK is the predominant kinase responsible for phosphorylating
MYPT1 at Thr853, while other Thr696 kinases may exist in human
myometrial tissue. Furthermore, as g-H-1152-treated strips showed
reduced contractility, the data demonstrate a positive relationship
between phosphorylation of MYL, MYPT1 and force in fresh myome-
trial tissue.
Phosphorylation of MYL and MYPT1
increases during OXT-stimulated phasic
myometrial contractions in vitro
The tension–phosphorylation relationship was explored further by
freezing myometrial tissue during the peak of a contraction or
during a relaxation phase. These studies were carried out on strips sti-
mulated with 10 nM OXT, and in the presence or absence of 1 mM
g-H-1152. Contractility traces showing the relaxing effect of 1 mM
g-H-1152 are shown in Fig. 3A and B. Table I describes the absolute
tension recorded during relaxed and contracting phases of OXT-
stimulated strips treated with either g-H-1152 or DMSO vehicle
control, highlighting the function of the strips at the time of freezing.
The phosphorylation of MYL and MYPT1 measured in these
samples is quantiﬁed in Fig. 3C–F. OXT-induced phasic contractions
were associated with signiﬁcant increases in MYL (Thr18/Ser19),
MYPT1 (Thr853) and MYPT (Thr696) phosphorylation (2.54+
0.61-fold, P , 0.01; 4.21+1.23-fold, P , 0.01 and 2.98+
0.57-fold, P , 0.01, respectively, n ¼ 7). There was evidence for
contraction-induced increases in pMYL (Ser19) but the effect failed
.............................................................................................................................................
........................................................ ..........................................................
.............................................................................................................................................................................................
Table I Tension of strips measured during the relaxed or contracting phases.
Treatment Tension (g)
Pretreatment Post-treatment
Relaxed Contracting Relaxed Contracting
OXT + DMSO 1.47+0.12 8.20+1.08* 1.82+0.15 8.00+1.0*
OXT + g-H-1152 1.91+0.22 8.21+1.05* 1.22+0.15 4.90+0.79*
†
DMSO 1.53+0.11 6.51+0.71* 1.47+0.12 6.23+0.75*
g-H-1152 1.51+0.15 5.85+0.40* 1.11+0.10 3.39+0.37*
†
Results are means+SEM, n ¼ 7 for both spontaneous and OXT-treated experiments. *P , 0.001 and
†P , 0.001 for the effect of contraction and treatment respectively, as
determined by two-way ANOVA and Bonferroni post hoc tests.
Phosphorylation of MYPT1 in human myometrium 271to reach statistical signiﬁcance. Interestingly, the contraction-induced
increases in ppMYL (Thr18/Ser19) and pMYPT (Thr853) were signiﬁ-
cantly attenuated in strips incubated with 1 mM g-H-1152 (P , 0.01,
Fig. 3C and E), while the increases in pMYPT1 (Thr696) were not.
This ﬁnding suggests a discrepancy between the afﬁnity of ROCK for
Thr853 and Thr696 of MYPT1 in human myometrium, and shows
that dynamic changes in MYPT phosphorylation occur during contrac-
tions. Furthermore, the data indicate that phosphorylation at Thr18,
resulting in dual phosphorylation of MYL, is more prominent during
phasic contractions than phosphorylation of MYL at Ser19 alone.
Phosphorylation of MYL and MYPT1 also
increases during spontaneous phasic
myometrial contractions
The studies were extended to non-stimulated, spontaneously con-
tracting strips. Contractility traces showing the relaxing effect of
1 mM g-H-1152 are shown in Fig. 4A and B. Table I describes the
absolute tension recorded during relaxed and contracting phases of
strips treated with either g-H-1152 or DMSO vehicle control. The
phosphorylation of MYL and MYPT1 measured in these samples is
quantiﬁed in Fig. 4C–F. Spontaneous phasic contractions were asso-
ciated with signiﬁcant increases in MYL (Thr18/Ser19), MYL
(Ser19), MYPT1 (Thr853) and MYPT (Thr696) phosphorylation
(3.10+0.74-fold P , 0.01; 1.91+0.41-fold, P , 0.05; 1.93+
0.23-fold, P , 0.05 and 2.35+0.28-fold, P , 0.05, respectively,
n ¼ 7). The contraction-induced increases in ppMYL (Thr18/Ser19)
were signiﬁcantly attenuated in strips incubated with 1 mM g-H-1152
(P , 0.01, Fig. 3D), comparable to the effect in OXT-stimulated
strips. The overall effect of g-H-1152 on pMYPT (Thr853) in these
experiments was signiﬁcant (two-way ANOVA; P , 0.05, Fig. 4E),
but the inhibitory effect of g-H-1152 was smaller than in OXT-
stimulated tissue. Comparing data from Figs 3 and 4, OXT caused a
greater fold effect on contraction-induced MYPT (Thr696 and
Thr853) phosphorylation than spontaneous contractions alone,
while the effects on MYL phosphorylation were similar in OXT-
stimulated and non-stimulated tissue. This observation was veriﬁed
when spontaneous and OXT-stimulated contractions were studied
simultaneously with the same tissue samples in a separate set of
experiments (data not shown).
g-H-1152-induced reductions in MYL and
MYPT1 phosphorylation in cultured
myometrial cells
Studies from tissue were extended to cultured myometrial cells to
investigate the involvement of ROCK in more detail. As shown in
Fig. 5, g-H-1152 caused a dose-dependent decrease in ppMYL
(Thr18/Ser19) with signiﬁcant effects from 50 nM (P , 0.01) and a
maximal 85.6+3.5% reduction at 1 mM g-H-1152, P , 0.01
(Fig. 5B). The effects on MYL (Ser19) phosphorylation were less
potent; phosphorylation was signiﬁcantly decreased after incubation
of cells with 500 nM g-H-1152 (P , 0.01), with a maximal reduction
at 1 mM of 45.3+5.9%, P , 0.01 (Fig. 5C). Figure 5D depicts a dose-
dependent decrease in pMYPT1 (Thr853) with a signiﬁcant reduction
from 50 nM g-H-1152 (P , 0.01) and a maximal decrease of 86.5+
2.9% at 1 mM g-H-1152 (P , 0.01); however, ROCK inhibition caused
a weaker reduction (maximum 24.2+7.2%, P , 0.01) in phosphoryl-
ation at Thr696 (Fig. 5E).
g-H-1152 does not attenuate PKC signalling
in cultured myometrial cells, and PKC
inhibition causes no signiﬁcant decreases in
MYL or MYPT1 phosphorylation
PKC is capable of phosphorylating CPI-17 at Thr38 leading to inhib-
ition of MYLP (Eto et al., 1995; Kitazawa et al., 2000), therefore it
could also contribute indirectly to increasing phosphorylated MYL
levels in myometrial cells. During pregnancy there is increased sensi-
tivity of human myometrial tissue to PKC inhibitors that decrease
spontaneous and OXT-induced contractions (Ozaki et al., 2003;
Yasuda et al., 2007). To examine the possibility that g-H-1152 may
be having off target effects through interference of PKC signalling,
we measured phosphorylation of a 30 kDa PKC protein substrate
likely to be S6 ribosomal protein (Zhang et al., 2002). Dose–response
studies with g-H-1152 and the PKC inhibitor bisindolylmaleimide I
(BIS1 or GF109203X) were run in parallel, and while BIS1 clearly inhib-
ited PKC activity from 100 nM (P , 0.05), g-H-1152 did not affect
PKC-dependent phosphorylation up to 1 mM (Fig. 6A and B). Further-
more, BIS1 failed to inhibit phosphorylation of MYL (Ser19 or Thr18/
Ser19) or MYPT1 (Thr853 or Thr696), whereas g-H-1152 had strong
inhibitory effects, as expected (Fig. 6C–G). The clear discrepancies
between the effects of g-H-1152 and BIS1 suggest that g-H-1152 is
unlikely to be mediating its inhibitory effects on MYL or MYPT phos-
phorylation through altering PKC activity.
ROCK inhibition with g-H-1152 causes
disassembly of stress ﬁbres in cultured
myometrial cells
Inhibition of ROCK with Y27632 has previously been shown to inhibit
stress ﬁbre formation in cultured myometrial cells (Gogarten et al.,
2001), therefore the effect of g-H-1152 on stress ﬁbres in our myome-
trial cultures was investigated. In resting cells, stress ﬁbres can be seen
to traverse the cells in parallel bundles as detected by F-actin staining
(Fig. 7A). Treatment of cells with 1 mM g-H-1152 caused an overall
reduction in F-actin staining and a noticeable decrease in individual
stress ﬁbres (Fig. 7B). In contrast, the PKC inhibitor BIS1 had no
effect on F-actin staining or stress ﬁbre morphology (Fig. 7C).
siRNA-mediated knockdown of both ROCK1
and ROCK2 results in a reduction in MYPT1
phosphorylation at Thr853 in cultured
myometrial cells
siRNAs targeting both ROCK1 and ROCK2 were used individually and
in combination to lower ROCK expression in cultured myometrial
cells, and an 80% reduction in ROCK1/2 protein expression was
achieved as demonstrated by immunoblotting (Fig. 8A–C). Knock-
down of both ROCK isoforms was accompanied by a signiﬁcant
reduction in pMYPT1 (Thr853) (51.2+5.0%, P , 0.01, n ¼ 8) and
modest decreases in ppMYL (Thr18/Ser19), pMYL (Ser19) and
pMYPT1 (Thr696) that did not reach statistical signiﬁcance (Fig. 8D,
E and G). These data support the results obtained in fresh tissue
and conﬁrm that Thr853 is the primary site of ROCK-mediated
272 Hudson et al.MYPT1 phosphorylation, and strongly suggest that both ROCK iso-
forms are involved.
siRNA-mediated knockdown of Rho-effectors
PKN1 or PKN2 does not affect MYL or MYPT
phosphorylation in cultured myometrial cells
Data from experiments utilizing g-H-1152 have been supported by
ROCK1/2 knockdown, and we have excluded the possibility that
g-H-1152 interferes with PKC activity. PKN1 and PKN2 are
members of the PKC superfamily and can be activated by Rho-family
members. We therefore investigated the involvement of PKN1/2 in
MYL and MYPT1 phosphorylation by siRNA-mediated knockdown.
Expression of PKN1 and PKN2 proteins was reduced by  90 and
96%, respectively, both individually and in combination, as demon-
strated by immunoblotting (P , 0.01, Fig. 9A–C). However, the
loss of PKN proteins was not associated with any signiﬁcant changes
in MYL or MYPT1 phosphorylation (Fig. 9D–G).
Discussion
Inhibition of MYLP and the consequent decrease in MYL depho-
sphorylation have been proposed as primary mechanisms of Ca
2+-
sensitization in smooth muscle (Somlyo and Somlyo, 1994). OXT
provokes Ca
2+-sensitization in myometrium (Woodcock et al.,
2004), however, phosphorylation of the sites on MYPT1
documented to cause auto-inhibition of the phosphatase (Thr696
and Thr853) has not been demonstrated previously in fresh human
myometrial tissue. In the present study, we used phosho-speciﬁc
antibodies to deﬁne the sites of MYPT1 phosphorylation in fresh
tissue and cultured myometrial cells and have employed the inhibitor
g-H-1152 to elucidate the role of ROCK. This study reveals that
inhibition of ROCK with g-H-1152 reduces spontaneous and OXT-
stimulated myometrial contractility and this reduction is associated
with decreased phosphorylation of MYL and MYPT1 in fresh myo-
metrial tissue. Moreover, we report for the ﬁrst time a positive
correlation between myometrial force and MYPT1 phosphorylation,
and show that increased phosphorylation of MYL and MYPT1 (in
particular on Thr18 and Thr853, respectively) during phasic contrac-
tions is ROCK-dependent. The fact that phosphorylation of MYPT1
(Thr853) changes so dynamically with each contraction is a very
interesting ﬁnding that could only be detected with this type of
experimental approach.
The effect of the ROCK inhibitor g-H-1152 on human myometrial
contractility in vitro has not been tested previously. Here, it caused
dose-dependent reductions in integrated area of phasic contractions
and baseline force of OXT-stimulated myometrial strips. This sup-
ports other studies using an alternative ROCK inhibitor, Y27632,
which reported decreases in amplitude and integrated area of
OXT-induced contractions (Moran et al., 2002; Woodcock et al.,
2004). However, other studies have suggested that inhibition of
ROCK with Y27632 only affects force when the myometrium is
Figure 5 ROCK inhibitor g-H-1152 causes dose-dependent decreases in MYL and MYPT1 phosphorylation in cultured myometrial cells. Resting
myometrial cells were treated for 40 min with g-H-1152 at the concentrations shown; 0.1% DMSO was added to control wells. (A) Cell lysates
were subjected to immunoblotting for total and phosphorylated MYL and MYPT1, representative blots are shown. Signal from the phospho-speciﬁc
antibody was normalized to that obtained from the associated total antibody, and was expressed as a percentage of the non-treated value. (B) ppMYL
(Thr18/Ser19) levels; (C) pMYL (Ser19) levels; (D) pMYPT1 (Thr853) levels and (E) pMYPT1 (Thr696) levels. Data points represent mean+SEM,
n ¼ 11. Statistical signiﬁcance was determined using one-way ANOVA and Dunnett’s post hoc test; *P , 0.05 and **P , 0.01 compared with non-
treated cells.
Phosphorylation of MYPT1 in human myometrium 273stimulated tonically after depolarization with high K
+, and has little
effect on OXT-stimulated phasic contractions (Kupittayanant et al.,
2001). It is important to note that we found signiﬁcant decreases
in integrated area (which is a robust overall assessment of contrac-
tions as it combines information about amplitude, rate and duration)
when we used g-H-1152 at 100 nM, only 10-fold higher than the
reported IC50 for ROCK2 (Tamura et al., 2005). At this concentra-
tion, g-H-1152 is unlikely to affect other kinases such as PKC or
MYLK, and these data suggest that ROCK activity contributes to
OXT-induced phasic contractility of myometrial tissue in vitro, and
would support a role for ROCK during labour in vivo. Previous ﬁnd-
ings from our laboratory indicating an increase in Rho-GTP with
spontaneous labour (Lartey et al., 2007) also support a role for aug-
mented Rho-ROCK signalling during phasic myometrial contractions
at the onset of labour.
Interestingly, when phosphorylation was examined in resting strips,
ROCK inhibition with g-H-1152 was associated with decreases in MYL
and MYPT1 phosphorylation, with pMYPT1 (Thr853) more affected
than pMYPT1 (Thr696). Baseline force was concomitantly reduced
by nearly 40% in these samples, thus we have demonstrated for the
ﬁrst time a positive correlation between force and MYPT1 phosphor-
ylation in human myometrial tissue.
Exploration of the relationship between contractility and phosphor-
ylation was extended when myometrial strips were frozen either
during or between spontaneous and OXT-stimulated phasic contrac-
tions. This methodology has proven successful in a recent paper
describing contraction-related increases in phosphorylation of high
molecular weight caldesmon (h-CaD) and extracellular signal-
regulated kinase 1/2 (ERK 1/2) (Paul et al., 2011). In our study,
phosphorylation of MYL (Thr18/Ser19) increased during
Figure 6 g-H-1152 does not attenuate PKC signalling and inhibition of conventional PKC isoforms causes no signiﬁcant decrease in MYL or MYPT1
phosphorylation.Restingmyometrialcellsweretreatedfor40 minwitheitherbisindolylmaleimideI(BIS1)org-H-1152attheconcentrationsshown;0.1%
DMSOwasaddedtocontrolwells.Bothcompoundswereusedintandemduringeachexperiment.Celllysatesweresubjectedtoimmunoblottingusinga
PKC substrate antibody (A) and antibodies to detect total and phosphorylated MYL and MYPT1 (C), representative blots are shown. Signals from
phospho-speciﬁc antibodies were normalized to those obtained from the associated total antibody, and were expressed as a percentage of the non-
treated value. (B) 30 kDa PKC substrate phosphorylation; (D) ppMYL (Thr18/Ser19) levels; (E) pMYL (Ser19) levels; (F) pMYPT1 (Thr853) levels
and (G) pMYPT1 (Thr696) levels. Data points represent mean+SEM, n ¼ 5, black: BIS1 and red: g-H-1152. Statistical signiﬁcance was determined
using two-way ANOVA and Bonferroni post hoc tests to compare both the effect of one compound against the other (a: P , 0.05, b: P , 0.01 and c:
P , 0.001) and the effect of increasing dose (a: P , 0.05, b: P , 0.05 and g: P , 0.001 compared with non-treated cells).
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results with g-H-1152 suggest that ROCK activity is required for
phosphorylation of MYL at Thr18 predominantly. Phosphorylation
of MYPT1 (Thr853) followed a similar pattern, therefore providing
evidence that MYL and MYPT1 phosphorylation are functionally
coupled with phasic contractility of myometrial strips in vitro, and
that ROCK activity is required. Phosphorylation of MYL and MYPT
also increased during spontaneous contractions, and
contraction-induced pMYL (Thr18/Ser19) showed signiﬁcant ROCK
dependency.
Figure 7 ROCK inhibitor g-H-1152 causes disassembly of actin stress ﬁbres in cultured myometrial cells. Representative examples of ﬁlamentous
actin (F-actin) staining with Alexa Fluor 488w -phalloidin in resting myometrial cells; (A) in the absence of inhibitors or (B) in the presence of 1 mM
ROCK inhibitor g-H-1152 or (C)2mM PKC inhibitor bisindolylmaleimide I (BIS1). Nuclear DNA was detected with DAPI (blue in insets). Wide-ﬁeld
images show decreases in overall F-actin staining (white) with ROCK inhibition, and insets highlight the parallel stress ﬁbre bundles (green) in cells
which decrease in the presence of ROCK inhibitor g-H-1152. Scale bars ¼ 500 and 50 mm in insets.
Figure 8 siRNA knockdown of ROCK1 and ROCK2 in cultured myometrial cells causes a signiﬁcant decrease in MYPT1 phosphorylation at
Thr853. Sub-conﬂuent myometrial cells were transfected with 25 nM siRNA targeted for ROCK1 (R1), ROCK2 (R2), both (R1/R2) or non-targeting
(scr) and grown for a further 72 h. (A) Cell lysates were subjected to immunoblotting for ROCK1, ROCK2, total and phosphorylated MYL and
MYPT1, representative blots are shown. Signals from the phospho-speciﬁc antibody when used were normalized to those obtained from the asso-
ciated total antibody, and data were expressed as a percentage of the non-transfected value. (B) ROCK1 levels; (C) ROCK2 levels; (D) ppMYL
(Thr18/Ser19) levels; (E) pMYL (Ser19) levels; (F) pMYPT1 (Thr853) levels and (G) pMYPT1 (Thr696) levels. Bars represent mean + SEM,
n ¼ 8. Statistical signiﬁcance was determined using one-way ANOVA and Dunnett’s post hoc test; **P , 0.01 compared with non-transfected cells.
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MYPT1 at Thr853 over Thr696 in cultured myometrial cells indicates
that basal ROCK activity is sufﬁcient for maintaining MYPT1 phosphor-
ylation at Thr853 under non-stimulated conditions. It appears that a
combination of kinases including ROCK are responsible for phosphor-
ylating MYPT1 at Thr696, and further work is required to elucidate the
identity of these. The observation that signiﬁcant decreases in MYPT1
(Thr853) and MYL (Thr18/Ser19) phosphorylation were observed at
only 50 nM g-H-1152 reduces the likelihood that non-speciﬁc effects
of the inhibitor were responsible. The possibility that g-H-1152 signiﬁ-
cantly affects PKC activity was ruled out by its inability to reduce phos-
phorylation of a PKC substrate. On the other hand, an inhibitor of
conventional PKC isoforms (bisindolylmaleimide I) effectively
decreased PKC substrate phosphorylation, while being unable to
inhibit MYL or MYPT phosphorylation.
A simultaneous 80% knockdown of ROCK1 and ROCK2 isoforms
was achieved in cultured human myometrial cells using siRNA and this
was associated with a signiﬁcant reduction in MYPT1 phosphorylation
at Thr853. This supports the hypothesis that Thr853 is the preferred
site for ROCK, and that both ROCK1 and ROCK2 isoforms are
involved. The reductions in MYPT1 and MYL phosphorylation were
less marked after ROCK knockdown in comparison to g-H-1152
treatment, and this discrepancy is likely due to the incomplete
silencing of ROCK by siRNA methodology, with 20% ROCK1/2
protein remaining. However, we cannot rule out the possibility that
g-H-1152 is inhibiting kinases other than ROCK, thereby exacerbating
its effects over those of siRNA knockdown. PKN1 and PKN2 were
proposed as candidates for such potential off-target effects of
g-H-1152 for the following reasons: they are also Rho-activated
kinases; PKN2 was partially inhibited by the non-glycyl H-1152 in an
in vitro assay (Bain et al., 2007); and we have shown PKN1 is
up-regulated in pregnancy (Lartey et al., 2007). However, successful
siRNA-mediated knockdown of both PKN1 and PKN2 individually
and in combination had no measurable effect, and suggests that
these kinases are not involved in maintaining resting levels of MYPT
or MYL phosphorylation in cultured myometrial cells. This result
further supports the speciﬁcity of g-H-1152 for ROCK.
When Thr853 is phosphorylated, the catalytic activity of MYLP is
inhibited by a process of auto-inhibition (Khromov et al., 2009) result-
ing in increased phosphorylation of MYL. Inhibition of phosphatase
activity following phosphorylation of MYPT1 is likely to contribute
to increased phosphorylation of MYL and phasic contractility as we
have reported dynamic changes in pMYPT (Thr853) during contrac-
tions. Moreover, phosphorylated CPI-17 (PPP1R14A), a substrate
for PKC, could also inhibit MYLP, but our data using the PKC inhibitor
bisindolylmaleimide 1 suggest that PKC-mediated pathways do not
Figure 9 siRNA knockdown of PKN1 and PKN2 in cultured myometrial cells has no effect on MYL or MYPT1 phosphorylation. Sub-conﬂuent
myometrial cells were transfected with 25 nM siRNA targeted for PKN1 (P1), PKN2 (P2), both (P1/P2) or non-targeting (scr) and grown for a
further 72 h. (A) Cell lysates were subjected to immunoblotting for PKN1, PKN2, total and phosphorylated MYL and MYPT1, representative
blots are shown. Signals from the phospho-speciﬁc antibody when used were normalized to those obtained from the associated total antibody,
and data were expressed as a percentage of the non-transfected value. (B) PKN1 levels; (C) PKN2 levels; (D) ppMYL (Thr18/Ser19) levels; (E)
pMYL (Ser19) levels; (F) pMYPT1 (Thr853) levels and (G) pMYPT1 (Thr696) levels. Bars represent mean + SEM, n ¼ 6. Statistical signiﬁcance
was determined using one-way ANOVA and Dunnett’s post hoc test; **P , 0.01 compared with non-transfected cells.
276 Hudson et al.play a role in maintaining phosphorylated MYL levels in myometrial
cells. However, ROCK-dependent phosphorylation and activation of
CPI-17 at Thr38 has been demonstrated in smooth muscle after
agonist stimulation (Pang et al., 2005; Patil and Bitar, 2006). Thus,
the regulation of CPI-17 by ROCK in the myometrium warrants
further study.
While the contribution to myometrial contractility of ROCK-
dependent MYLP inhibition is signiﬁcant, its role is likely to be comple-
mentary to the substantial contribution of Ca
2+-MYLK signalling
(Wray et al., 2001). Inhibition of MYLK with wortmannin can
completely ablate both spontaneous and OXT-induced contractions
of human myometrium, highlighting the importance of Ca
2+-MYLK
activity (Longbottom et al., 2000), however, this ﬁnding does not
exclude the possibility of ROCK-dependent Ca
2+-sensitization in
conjunction with Ca
2+-MYLK signalling. The signiﬁcant effect of
g-H-1152 in the current study suggests that MYL phosphorylation is
elevated during phasic contractions by both activation of MYLK and
by ROCK-dependent mechanisms, including inhibition of phosphatase
activity. However, without simultaneous measurements of [Ca
2+]i and
force we cannot be sure that g-H-1152 treatment is blocking Ca
2+-
sensitization. Uncoupling of [Ca
2+]i and force has been demonstrated
by others in response to OXT; there is evidence that the Ca
2+-
sensitizing effects of OXT are ROCK-dependent (Woodcock et al.,
2004) and that they occur during the falling phase of the contraction
(McKillen et al., 1999). Interestingly, the Ca
2+-force relationship
evoked by OXT is the same in myometrium taken before or after
the onset of labour (McKillen et al., 1999).
Throughout our studies, inhibition of ROCK was less effective at
decreasing pMYL (Ser19) than ppMYL (Thr18/Ser19), suggesting
that phosphorylation of Thr18 shows greater ROCK dependency
than phosphorylation of Ser19. If the action of ROCK is solely
mediated via phosphatase inhibition then this discrepancy can be
explained by concluding that MYLP acts preferentially on Thr18 of
MYL. Alternatively, these data suggest that ROCK is capable of phos-
phorylating Thr18 of MYL directly during contractions, providing a
ROCK-dependent but phosphatase-independent mechanism of force
generation. In vitro phosphorylation of MYL by ROCK, primarily at
Ser19, has been described (Amano et al., 1996; Ueda et al., 2002),
and ROCK causes contraction of stress ﬁbres isolated from human
ﬁbroblasts (Katoh et al., 2001). It is possible that ROCK-mediated
phosphorylation of Thr18 occurs following Ca
2+-dependent, MYLK-
mediated phosphorylation of Ser19; however, the current data are
limited and these possibilities require further investigation. Neverthe-
less, our data indicate that phosphorylation of MYL at Thr18 is more
dynamically regulated during phasic contractions than phosphorylation
of Ser19, and this supports an important role for MYL (Thr18) phos-
phorylation in human myometrium.
In summary, our ﬁndings provide strong evidence for ROCK-
dependent phosphorylation of MYL (Thr18) and MYPT1 (Thr853)
during spontaneous and OXT-stimulated phasic contractions of
fresh human myometrial tissue in vitro. Pharmacological inhibition of
ROCK is associated with decreases in OXT-stimulated myometrial
contractility as determined by integrated area of phasic contractions
and baseline force, strongly suggesting that ROCK-mediated inhibition
of phosphatase activity makes an important contribution to the regu-
lation of contractility in human myometrium. These data increase our
understanding of the control of human myometrial activity and warrant
further studies to investigate whether aberrations in ROCK signalling
may contribute to increased contractility in preterm labour.
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